Valeria Masiello

Dr. Valeria Masiello

Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2020 in Cancers
Verified
Journal Article
Open access
PDF file
FMFabio Marazzi
Fabio Marazzi
Armando OrlandiArmando Orlandi
Armando Orlandi
SMStefania Manfrida
Stefania Manfrida
VMValeria Masiello
Valeria Masiello
Alba Di LeoneAlba Di Leone
Alba Di Leone
VVVincenzo Valentini
Vincenzo Valentini
The standard care for metastatic breast cancer (MBC) is systemic therapies with imbrication of focal treatment for symptoms. Recently, thanks to implementation of radiological and metabolic exams and development of new target therapies, oligometastatic and oligoprogressive settings are even more common—paving the way to a paradigm change of focal treatments role. In fact, according to immunophenotype, radiotherapy can be considered with radical intent in these settings of patients. The aim of this literature review is to analyze available clinical data on prognosis of bone metastases from breast cancer and benefits of available treatments for developing a practical guide for clinicians.

19 December 2018 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
STSilvia Taralli
Silvia Taralli
MLMargherita Lorusso
Margherita Lorusso
VSValentina Scolozzi
Valentina Scolozzi
VMValeria Masiello
Valeria Masiello
FMFabio Marazzi
Fabio Marazzi
MCMaria Lucia Calcagni
Maria Lucia Calcagni

1 January 2015 in Journal of Contemporary Brachytherapy
Verified
Journal Article
Open access
LTLuca Tagliaferri
Luca Tagliaferri
SMStefania Manfrida
Stefania Manfrida
BBBrunella Barbaro
Brunella Barbaro
MCMaria Maddalena Colangione
Maria Maddalena Colangione
VMValeria Masiello
Valeria Masiello
VVVincenzo Valentini
Vincenzo Valentini
Purpose : The aim of this study is to test a novel multiparametric imaging guided procedure for high-dose- rate brachytherapy in anal canal cancer, in order to evaluate the feasibility and safety. Material and methods : For this analysis, we considered all consecutive patients who underwent...

24 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
EMElisa Meldolesi
Elisa Meldolesi
GCGiuditta Chiloiro
Giuditta Chiloiro
RGRoberta Giannini
Roberta Giannini
RMRoberta Menghi
Roberta Menghi
RPRoberto Persiani
Roberto Persiani
Maria Antonietta GambacortaMaria Antonietta Gambacorta
Maria Antonietta Gambacorta
Aims: Between 11 to 14% of patients with locally advanced rectal cancer (LARC) have positive lateral pelvic lymph nodes (LPLN) at diagnosis, related to a worse prognosis with a 5-year survival rate between 30 to 40%. The best treatment choice for this group of patients is still a challenge. The optimal radiotherapy (RT) dose for LPLN patients has been investigated. Methods: We retrospectively collected data from LARC patients with LPLN at the primary staging MRI, treated in our center from March 2003 to December 2020. Patients underwent a neoadjuvant concomitant chemo-radiotherapy (CRT) treatment on the primary tumor (T), mesorectum, and pelvic nodes, associated with a fluoride-based chemotherapy. The total reached dose was 45 Gy at 1.8 Gy/fr on the elective sites and 55 Gy at 2.2 Gy/fr on the disease and mesorectum. Patients were divided in two groups based on whether they received a simultaneous integrated RT boost on the LPLN or not. Overall Survival (OS), Disease Free Survival (DFS), Metastasis Free Survival (MFS), and Local Control (LC) were evaluated in the whole group and then compared between the two groups. Results: A total of 176 patients were evaluated: 82 were included in the RT boost group and 94 in the non-RT boost group. The median follow-up period was 57.8 months. All the clinical endpoint (OS, DFS, MFS, LC), resulted were affected by the simultaneous integrated boost on LPLN with a survival rate of 84.7%, 79.5%, 84.1%, and 92%, respectively, in the entire population. From the comparison of the two groups, there was a statistical significance towards the RT boost group with a p < 0.006, 0.030, 0.042, 0.026, respectively. Conclusions: Concomitant radiotherapy boost on positive LPLN has shown to be beneficial on the survival outcomes (OS, DFS, MFR, and LC) in patients with LARC and LPLN. This analysis demonstrates that a higher dose of radiotherapy on positive pelvic lymph nodes led not only to a higher local control but also to a better survival rate. These results, if validated by future prospective studies, can bring a valid alternative to the surgery dissection without the important side effects and permanent disabilities observed during the years.

1 October 2020 in Diagnostic and Interventional Imaging
Verified
Journal Article
Closed access
RRR. Rella
R. Rella
EBE. Bufi
E. Bufi
PBP. Belli
P. Belli
FPF. Petta
F. Petta
TST. Serra
T. Serra
RMR. Manfredi
R. Manfredi

Verified
Journal Article
Open access
PDF file
FMFabio Marazzi
Fabio Marazzi
LTLuca Tagliaferri
Luca Tagliaferri
VMValeria Masiello
Valeria Masiello
FMFrancesca Moschella
Francesca Moschella
GCGiuseppe Ferdinando Colloca
Giuseppe Ferdinando Colloca
VVVincenzo Valentini
Vincenzo Valentini
Background: Artificial Intelligence (AI) is increasingly used for process management in daily life. In the medical field AI is becoming part of computerized systems to manage information and encourage the generation of evidence. Here we present the development of the application of AI to IT systems present in the hospital, for the creation of a DataMart for the management of clinical and research processes in the field of breast cancer. Materials and methods: A multidisciplinary team of radiation oncologists, epidemiologists, medical oncologists, breast surgeons, data scientists, and data management experts worked together to identify relevant data and sources located inside the hospital system. Combinations of open-source data science packages and industry solutions were used to design the target framework. To validate the DataMart directly on real-life cases, the working team defined tumoral pathology and clinical purposes of proof of concepts (PoCs). Results: Data were classified into “Not organized, not ‘ontologized’ data”, “Organized, not ‘ontologized’ data”, and “Organized and ‘ontologized’ data”. Archives of real-world data (RWD) identified were platform based on ontology, hospital data warehouse, PDF documents, and electronic reports. Data extraction was performed by direct connection with structured data or text-mining technology. Two PoCs were performed, by which waiting time interval for radiotherapy and performance index of breast unit were tested and resulted available. Conclusions: GENERATOR Breast DataMart was created for supporting breast cancer pathways of care. An AI-based process automatically extracts data from different sources and uses them for generating trend studies and clinical evidence. Further studies and more proof of concepts are needed to exploit all the potentials of this system.